What is a common disadvantage of dobutamine therapy?

What is a common disadvantage of dobutamine therapy?

• A. Tachyphylaxis
• B. Hyperkalemia
• C. Nephrotoxicity
• D. Hyperglycemia

Answer: (A)

Dobutamine boosts heart muscle contractility by activating beta-1 receptors, which raises cAMP and calcium in cardiac cells to increase stroke volume and cardiac output. A common disadvantage of continuing dobutamine is tachyphylaxis—receptor desensitization with prolonged exposure—so the same dose becomes less effective over time. This waning response often forces dose adjustments or switching to another agent, but it also raises the risk of needing higher doses, which can amplify heart rate, arrhythmias, and myocardial oxygen demand. Hyperkalemia, nephrotoxicity, and hyperglycemia are not typically driven by dobutamine in the same way and are less relevant concerns in this context.

Dobutamine boosts heart muscle contractility by activating beta-1 receptors, which raises cAMP and calcium in cardiac cells to increase stroke volume and cardiac output. A common disadvantage of continuing dobutamine is tachyphylaxis—receptor desensitization with prolonged exposure—so the same dose becomes less effective over time. This waning response often forces dose adjustments or switching to another agent, but it also raises the risk of needing higher doses, which can amplify heart rate, arrhythmias, and myocardial oxygen demand. Hyperkalemia, nephrotoxicity, and hyperglycemia are not typically driven by dobutamine in the same way and are less relevant concerns in this context.